BioLineRx (BLRX) Net Cash Flow (2013 - 2025)

BioLineRx's Net Cash Flow history runs 13 years deep, the most recent figure standing at -$4.8 million for Q4 2025.

• In Q4 2025, Net Cash Flow fell 433.03% year-over-year to -$4.8 million; the TTM figure through Dec 2025 stood at -$7.7 million (down 225.59% YoY), while the FY2025 annual figure was -$7.7 million, down 225.59% from the prior year.
• Net Cash Flow was -$4.8 million for Q4 2025 at BioLineRx, down from $651000.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $3.9 million in Q2 2024 to a low of -$4.8 million in Q4 2025.
• Historically, Net Cash Flow has averaged -$676400.0 across 5 years, with a median of -$1.1 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 218.34% in 2024, then plunged 433.03% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$1.3 million in 2021, then sank by 85.42% to -$2.5 million in 2022, then sank by 48.46% to -$3.7 million in 2023, then jumped by 139.25% to $1.4 million in 2024, then slumped by 433.03% to -$4.8 million in 2025.
• The last three Net Cash Flow figures came in at -$4.8 million (Q4 2025), $651000.0 (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.